MX2021007327A - Fucosilacion controlada de anticuerpos. - Google Patents

Fucosilacion controlada de anticuerpos.

Info

Publication number
MX2021007327A
MX2021007327A MX2021007327A MX2021007327A MX2021007327A MX 2021007327 A MX2021007327 A MX 2021007327A MX 2021007327 A MX2021007327 A MX 2021007327A MX 2021007327 A MX2021007327 A MX 2021007327A MX 2021007327 A MX2021007327 A MX 2021007327A
Authority
MX
Mexico
Prior art keywords
antibodies
antibody
derivatives
derivative
fucosylation
Prior art date
Application number
MX2021007327A
Other languages
English (en)
Inventor
Shanta Boddapati
Aaron Chen
Swapnil Bhargava
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MX2021007327A publication Critical patent/MX2021007327A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención proporciona métodos para preparar anticuerpos y derivados de anticuerpos con niveles controlados de fucosilación del núcleo.
MX2021007327A 2018-12-19 2019-12-18 Fucosilacion controlada de anticuerpos. MX2021007327A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862781691P 2018-12-19 2018-12-19
PCT/US2019/067222 WO2020132096A1 (en) 2018-12-19 2019-12-18 Controlled fucosylation of antibodies

Publications (1)

Publication Number Publication Date
MX2021007327A true MX2021007327A (es) 2021-09-08

Family

ID=71100565

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007327A MX2021007327A (es) 2018-12-19 2019-12-18 Fucosilacion controlada de anticuerpos.

Country Status (11)

Country Link
US (1) US20220081477A1 (es)
EP (1) EP3897664A4 (es)
JP (1) JP2022514299A (es)
KR (1) KR20210104837A (es)
CN (1) CN113438951A (es)
AU (1) AU2019402923A1 (es)
CA (1) CA3123591A1 (es)
IL (1) IL284086A (es)
MX (1) MX2021007327A (es)
SG (1) SG11202106481SA (es)
WO (1) WO2020132096A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022081824A1 (en) * 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013201195A1 (en) * 2006-10-24 2013-03-21 Emergent Product Development Seattle, Llc A method for increasing antibody-dependent cytotoxicity with castanospermine
US8163551B2 (en) * 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
CA2963720C (en) * 2014-10-29 2024-05-14 Seattle Genetics, Inc. Dosage and administration of non-fucosylated anti-cd40 antibodies
US20180353524A1 (en) * 2015-12-04 2018-12-13 Seattle Genetics, Inc. Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
CN109153716A (zh) * 2016-01-06 2019-01-04 安口生物公司 调节单克隆抗体组合物中的非岩藻糖基化物类
IL311107A (en) * 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd

Also Published As

Publication number Publication date
SG11202106481SA (en) 2021-07-29
EP3897664A4 (en) 2022-12-07
KR20210104837A (ko) 2021-08-25
AU2019402923A1 (en) 2021-07-15
JP2022514299A (ja) 2022-02-10
IL284086A (en) 2021-08-31
CA3123591A1 (en) 2020-06-25
CN113438951A (zh) 2021-09-24
EP3897664A1 (en) 2021-10-27
US20220081477A1 (en) 2022-03-17
WO2020132096A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
MX2018008010A (es) Composicion y metodo para el crecimiento del pelo.
MX2020003381A (es) Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.
AU2012282775A8 (en) Settable compositions comprising interground perlite and hydraulic cement
MX2019010222A (es) Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina.
EP3743074A4 (en) COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
MX2022001764A (es) Composiciones que comprenden tigolaner para el control de parasitos.
EP4327880A3 (en) Solid state form of ribociclib succinate
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
EP3677126A4 (en) COMPOSITION OF AGE INHIBITORS, ITS USE, PROCESS OF PREPARATION AND ITS FORMULATION
MX2021007327A (es) Fucosilacion controlada de anticuerpos.
MX2021011995A (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso.
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
MY152388A (en) Composition and method for controlling plant diseases
EP3915538A4 (en) FAB-I INHIBITOR INJECTION COMPOSITION AND METHOD OF MANUFACTURE THEREOF
EP3970698A4 (en) INJECTABLE COMPOSITION WITH PRODRUG OF CASPASE INHIBITORS AND METHOD OF MANUFACTURE THEREOF
PL408608A1 (pl) Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
EP3998063A4 (en) COMPOSITIONS FOR PREPARING MICROEMULSION, MICROEMULSION, METHOD FOR PRODUCING COMPOSITION AND MICROEMULSION, AND USE OF MICROEMULSION
CR20220293A (es) Tieniloxazolonas y análogos
CR20220292A (es) Tiofenocarboxamidas sustituidas y sus derivados
EP4028058A4 (en) COMPOSITIONS AND METHODS FOR PRODUCING AND USING MULTISPECIFIC ANTIBODIES
WO2020055359A3 (en) Oral dosage form of sorafenib tosylate
WO2020101596A3 (en) A capsule composition comprising sunitinib
EP3815714A4 (en) COATING COMPOSITION AS WELL AS SOLID PREPARATION INTENDED TO BE ADMINISTERED ORALLY AND METHOD FOR MAKING IT